Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up
Language English Country Germany Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Time MeSH
- Child MeSH
- Hepatitis Antigens blood immunology MeSH
- Hepatitis B Antibodies blood immunology MeSH
- Hepatitis B immunology prevention & control virology MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Follow-Up Studies MeSH
- Infant, Newborn MeSH
- Immunization Schedule MeSH
- Child, Preschool MeSH
- Pregnancy MeSH
- Hepatitis B Vaccines administration & dosage immunology MeSH
- Vaccination MeSH
- Infectious Disease Transmission, Vertical prevention & control MeSH
- Hepatitis B virus immunology MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Hepatitis Antigens MeSH
- Hepatitis B Antibodies MeSH
- Hepatitis B Vaccines MeSH
BACKGROUND: Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown. PATIENTS AND METHODS: A combined passive-active immunization programme for newborns of HBsAg-positive mothers was initiated in the north-eastern part of the Czech Republic in 1988. The number of immunized newborns had reached 665 newborns by the end of 2006. All mothers of immunized infants were HBsAg-positive during pregnancy, and 34 (5%) were also hepatitis B e antigen (HBeAg)-positive. The immunization programme consists of providing newborns with protection at birth with hepatitis B immunoglobulin, followed by three 10-μg doses of plasma-derived or, since 1990, recombinant vaccine administered at 0, 1 and 6 months of life. Only 29 children of HBeAg-positive mothers received vaccine at 0, 1 and 2 months of life. Blood samples were obtained after immunization, at 2 years of age, and biennially thereafter. Samples were tested for HBsAg and hepatitis B surface and core antibodies (anti-HBs, anti-HBc). RESULTS: The immunization schedules were completed in 640 children. A protective anti-HBs level after immunization was proven in 574 of 620 children (93%). Persistence of protective anti-HBs antibodies was detected in 70, 40 and 25% of children at 5, 10 and 15 years of age. Vertical transmission with chronic HBsAg carrier status was detected in two infants. Anti-HBc seroconversion was proven in ten children from 3 to 15 years of age. Natural boosting with an anti-HBs increase was detected in 38 children (twice in one child). CONCLUSION: Our results show that combined active-passive immunization of newborns against hepatitis B provides persistent protection up to adolescence despite a frequent waning of anti-HBs antibodies, suggesting there is no need for booster vaccination during adolescence.
See more in PubMed
Hepatology. 1999 Mar;29(3):954-9 PubMed
J Infect Dis. 2009 Jul 1;200(1):33-8 PubMed
Lancet. 2000 Feb 12;355(9203):561-5 PubMed
BMJ. 2006 Feb 11;332(7537):328-36 PubMed
Am J Med. 2005 Oct;118 Suppl 10A:34S-39S PubMed
J Med Virol. 2000 May;61(1):11-4 PubMed
Arch Virol. 2009;154(3):437-43 PubMed
Vaccine. 2007 Sep 28;25(39-40):6958-64 PubMed
Infection. 2009 Aug;37(4):340-3 PubMed
Hepatology. 1999 Mar;29(3):924-7 PubMed
J Infect Dis. 2006 Jun 1;193(11):1528-35 PubMed
J Med Virol. 2009 Sep;81(9):1517-24 PubMed
